Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
Community
/
United States
/
Healthcare
Create a narrative
PROCEPT BioRobotics Community
NasdaqGM:PRCT Community
3
Narratives
written by author
0
Comments
on narratives written by author
16
Fair Values set
on narratives written by author
Community Investing Ideas
PROCEPT BioRobotics
Popular
Undervalued
Overvalued
PROCEPT BioRobotics
AN
AnalystLowTarget
Consensus Narrative from 8 Analysts
Competitive Pressures Will Hinder Urologic Procedures Yet Spur Progress
Key Takeaways Growth potential driven by demographic trends and innovation faces threats from competition, pricing pressure, and possible market shifts to non-device treatments. Expansion and recurring revenue are promising, but high costs, reimbursement risks, and geopolitical factors could constrain margins and profitability.
View narrative
US$51.00
FV
24.3% undervalued
intrinsic discount
26.33%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
4 days ago
author updated this narrative
PROCEPT BioRobotics
AN
AnalystHighTarget
Consensus Narrative from 8 Analysts
Aging Population And Robotic Advances Will Unlock Urologic Potential
Key Takeaways Accelerated adoption, streamlined reimbursement, and demographic trends are expected to drive stronger-than-expected revenue growth, operating leverage, and recurring handpiece demand. Expansion into new procedure categories and global markets, backed by clinical trials, strong cash reserves, and experienced leadership, positions the company for substantial long-term upside.
View narrative
US$85.00
FV
54.6% undervalued
intrinsic discount
32.94%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
5 days ago
author updated this narrative
PROCEPT BioRobotics
AN
AnalystConsensusTarget
Consensus Narrative from 8 Analysts
Clinical Adoption And Global Expansion Will Redefine Healthcare
Key Takeaways Expanded reimbursement and increased adoption promise accelerated revenue growth and margin expansion, as Aquablation becomes a standard for minimally invasive therapy in more hospitals. International growth, successful clinical trials, and new approvals are unlocking additional long-term revenue streams and expanding market reach for sustained profitability.
View narrative
US$65.75
FV
41.3% undervalued
intrinsic discount
26.99%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
14
users have followed this narrative
Updated
narrative
Your Valuation for
PRCT
PRCT
PROCEPT BioRobotics
Your Fair Value
US$
Current Price
US$38.60
56.3% overvalued
intrinsic discount
Growth estimate over
Annual revenue growth rate
5 Years
time period
%/yr
Decrease
Increase
Past
Future
-105m
690m
2015
2018
2021
2024
2025
2027
2030
Revenue US$690.0m
Earnings US$98.7m
Advanced
Set Fair Value